Neurocrine Biosciences, Inc.

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
142.3 ^USD	+0.27%		+4.09%	+7.99%

05-16	Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing	MT
05-14	Transcript : Neurocrine Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

May 01, 2024 at 12:00 pm

Neurocrine Biosciences, Inc. reaffirmed sales guidance for the full year of 2024. For the year, company expects INGREZZA Net Product Sales of $2,100 million to $2,200 million.

Latest news about Neurocrine Biosciences, Inc.

Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing	05-16	MT
Transcript : Neurocrine Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM	05-14
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024	05-14	CI
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024	05-09	CI
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	05-08	CI
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024	05-07	CI
Neurocrine Biosciences Presents CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024	05-03	CI
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating	05-02	MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating	05-02	MT
Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell	05-01	MT
Transcript : Neurocrine Biosciences, Inc., Q1 2024 Earnings Call, May 01, 2024	05-01
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q1 Revenue $515.3M, vs. Street Est of $512M	05-01	MT
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Reports Q1 EPS $1.20, vs. Street Est of $1.29	05-01	MT
Neurocrine Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024	05-01	CI
Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours	04-30	MT
Neurocrine Biosciences' Huntington's disease drug gets FDA approval	04-30	RE
FDA approves Neurocrine Biosciences' Huntington's disease drug	04-30	RE
Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules	04-30	CI
Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170	04-24	MT
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community	04-24	CI
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder	04-23	CI
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	04-17	MT
Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development	04-16	MT
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides	04-16	CI

Chart Neurocrine Biosciences, Inc.

Duration

Period

More charts

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntingtonâs disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Sector

Biotechnology & Medical Research

Calendar

22/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Neurocrine Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

142.3 USD

Average target price

158.4 USD

Spread / Average Target

+11.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B
LEGEND BIOTECH CORPORATION	-24.95%	8.23B

Bio Therapeutic Drugs